NASDAQ:VRAY - Viewray Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Viewray Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.23 +0.10 (+3.19 %) (As of 01/29/2020 12:58 PM ET) Add Compare Today's Range$3.11Now: $3.23▼$3.3150-Day Range$2.70MA: $3.83▼$4.6052-Week Range$2.12Now: $3.23▼$9.76Volume617,784 shsAverage Volume3.96 million shsMarket Capitalization$321.09 millionP/E RatioN/ADividend YieldN/ABeta1.17 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VRAY Previous Symbol CUSIPN/A CIK1597313 Webhttp://www.viewray.com/ Phone440-703-3210Debt Debt-to-Equity Ratio0.62 Current Ratio3.70 Quick Ratio2.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$80.96 million Price / Sales3.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book1.85Profitability EPS (Most Recent Fiscal Year)($0.98) Net Income$-76,400,000.00 Net Margins-110.61% Return on Equity-75.41% Return on Assets-37.32%Miscellaneous EmployeesN/A Outstanding Shares99,410,000Market Cap$321.09 million Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive VRAY News and Ratings via Email Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:VRAY Rates by TradingView Viewray (NASDAQ:VRAY) Frequently Asked Questions What is Viewray's stock symbol? Viewray trades on the NASDAQ under the ticker symbol "VRAY." How were Viewray's earnings last quarter? Viewray Inc (NASDAQ:VRAY) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.21) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.06. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. The business's revenue for the quarter was up 18.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.39) earnings per share. View Viewray's Earnings History. When is Viewray's next earnings date? Viewray is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Viewray. What guidance has Viewray issued on next quarter's earnings? Viewray updated its fourth quarter 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $17-17 million, compared to the consensus revenue estimate of $18.27 million. What price target have analysts set for VRAY? 9 Wall Street analysts have issued 1-year price objectives for Viewray's stock. Their forecasts range from $5.00 to $9.00. On average, they anticipate Viewray's share price to reach $6.44 in the next year. This suggests a possible upside of 99.5% from the stock's current price. View Analyst Price Targets for Viewray. What is the consensus analysts' recommendation for Viewray? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viewray in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viewray. What are Wall Street analysts saying about Viewray stock? Here are some recent quotes from research analysts about Viewray stock: 1. According to Zacks Investment Research, "ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio. " (11/16/2019) 2. Northland Securities analysts commented, "We remain confident in our analysis of the clinical benefits of MRgRT, and this study is another data point towards long-term validation." (8/19/2019) 3. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight rating and $13 PT on VRAY. 1Q revenue of $20.3MM (-23%) was essentially in line with FactSet consensus of $20.4MM. We think the order beat is a better measure of the momentum of the business. VRAY received orders for seven MRIdians, two more than we were expecting for the second straight quarter. We think the order momentum is a direct result of the strategy that the new management team has implemented since taking over in July 2018. The finishing touches of management’s strategy are still coming together, but we think VRAY is positioned to capitalize on what we expect to be meaningful shift to adaptive therapy and MR linacs." (5/2/2019) Has Viewray been receiving favorable news coverage? Media headlines about VRAY stock have trended negative on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Viewray earned a media sentiment score of -2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Viewray. Who are some of Viewray's key competitors? Some companies that are related to Viewray include Natus Medical (NTUS), AxoGen (AXGN), TransMedics Group (TMDX), Cutera (CUTR), Semler Scientific (SMLR), Zynex (ZYXI), Stereotaxis (STXS), BioLife Solutions (BLFS), Rockwell Medical (RMTI), Soleno Therapeutics (SLNO), Fonar (FONR), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES) and IRIDEX (IRIX). What other stocks do shareholders of Viewray own? Based on aggregate information from My MarketBeat watchlists, some companies that other Viewray investors own include Alibaba Group (BABA), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Amarin (AMRN), Amicus Therapeutics (FOLD), Iovance Biotherapeutics (IOVA), Progenics Pharmaceuticals (PGNX), Pieris Pharmaceuticals (PIRS) and Sarepta Therapeutics (SRPT). When did Viewray IPO? (VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers. Who are Viewray's major shareholders? Viewray's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.75%), Kahn Brothers Group Inc. DE (0.54%), Pennsylvania Trust Co (0.13%), California Public Employees Retirement System (0.13%), Joel Isaacson & Co. LLC (0.11%) and Alpine Global Management LLC (0.08%). Company insiders that own Viewray stock include Fmr Llc, International Ltd Fosun, James F Dempsey, Orbimed Advisors Llc, Scott William Drake and Shahriar Matin. View Institutional Ownership Trends for Viewray. Which major investors are buying Viewray stock? VRAY stock was bought by a variety of institutional investors in the last quarter, including Kahn Brothers Group Inc. DE, California Public Employees Retirement System, Rhenman & Partners Asset Management AB, Joel Isaacson & Co. LLC, Alpine Global Management LLC, SG Americas Securities LLC, Falcon Point Capital LLC and Pennsylvania Trust Co. Company insiders that have bought Viewray stock in the last two years include International Ltd Fosun, Scott William Drake and Shahriar Matin. View Insider Buying and Selling for Viewray. How do I buy shares of Viewray? Shares of VRAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Viewray's stock price today? One share of VRAY stock can currently be purchased for approximately $3.23. How big of a company is Viewray? Viewray has a market capitalization of $321.09 million and generates $80.96 million in revenue each year. The company earns $-76,400,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. View Additional Information About Viewray. What is Viewray's official website? The official website for Viewray is http://www.viewray.com/. How can I contact Viewray? Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 440-703-3210 or via email at [email protected] MarketBeat Community Rating for Viewray (NASDAQ VRAY)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 252 (Vote Outperform)Underperform Votes: 191 (Vote Underperform)Total Votes: 443MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe VRAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRAY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/29/2020 by MarketBeat.com StaffFeatured Article: What is the Beige Book?
